Positive opinion for new multiple myeloma drug

The European Medicines Agency’s (EMA): Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Pomalidomide in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (rrMM) in patients who have received at least two prior therapies, including both lenalidomide and bortezomib, and have demonstrated disease progression while on their last therapy.   Multiple myeloma is the second most common cancer of the blood and accounts for around 1% of all cases of cancer in the UK. Multiple myeloma remains incurable and nearly all patients who achieve an initial response to treatment will relapse and